AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis
- Details
- Category: AstraZeneca
The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation.
This interim safety and efficacy analysis was based on 32,449 participants accruing 141 symptomatic cases of COVID-19. The trial had a 2:1 randomisation of vaccine to placebo.
Bharat Biotech announces Phase 3 results of COVAXIN®: India's first COVID-19 vaccine demonstrates interim clinical efficacy of 81%
- Details
- Category: Business
Bharat Biotech, a global leader in vaccine innovation, developing vaccines for infectious diseases, announced the first interim analysis of its BBV152 (COVAXIN®). The whole virion inactivated COVID-19 vaccine candidate demonstrated an interim vaccine efficacy of 81% in its Phase 3 clinical trial.
UK and EU regulatory agencies confirm COVID-19 Vaccine AstraZeneca is safe and effective
- Details
- Category: AstraZeneca
Today the Medicines Health Regulatory Authority (MHRA) and European Medicines Agency (EMA) reaffirmed the benefits of COVID-19 Vaccine AstraZeneca continue to far outweigh the risks.
Earlier today, the MHRA announced their review of the small number of thromboembolic events in over 11 million people who received COVID-19 Vaccine AstraZeneca in the UK.
Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate
- Details
- Category: Sanofi
Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the virus that causes COVID-19.
WHO statement on AstraZeneca COVID-19 vaccine safety signals
- Details
- Category: Business
Some countries in the European Union have temporarily suspended use of the AstraZeneca COVID-19 vaccine as a precautionary measure based on reports of rare blood coagulation disorders in persons who had received the vaccine. Other countries in the EU - having considered the same information - have decided to continue using the vaccine in their immunization programmes.
Agreement builds on an earlier announcement that included support for the clinical development and supply of the treatment
- Details
- Category: AstraZeneca
AstraZeneca has modified an existing agreement with the US Government to supply up to 500,000 additional doses of AZD7442, a long-acting antibody (LAAB) combination which is in late-stage development for the prevention and treatment of COVID-19.
First participants dosed in Phase 1 study evaluating mRNA-1283, Moderna's next generation COVID-19 vaccine
- Details
- Category: Business
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participants have been dosed in the Phase 1 study of mRNA-1283, the Company's next generation COVID-19 vaccine candidate.
More Pharma News ...
- Update on the safety of COVID-19 Vaccine AstraZeneca
- Abbott announces its Pandemic Defense Coalition
- Real-world evidence confirms high effectiveness of Pfizer-BioNTech COVID-19 vaccine and profound public health impact of vaccination one year after pandemic declared
- Abbott introduces NeuroSphere™ Virtual Clinic, first-of-its-kind remote neuromodulation patient-care technology in the U.S.
- EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union
- Johnson & Johnson announces aingle-ahot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of its Phase 3 ENSEMBLE trial
- Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate